Five-year analysis of the POLARIX study: Prolonged follow-up confirms positive impact of polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) on outcomes Meeting Abstract
| Authors: | Salles, G.; Morschhauser, F.; Sehn, L. H.; Herrera, A. F.; Friedberg, J. W.; Trněný, M.; Lenz, G.; Sharman, J. P.; Herbaux, C.; Burke, J. M.; Matasar, M.; Collins, G. P.; Song, Y.; Pinto, A.; Rai, S.; Izutsu, K.; Lee, C.; Chohan, S.; Sugidono, M.; Jiang, Y.; Batlevi, C. L.; Yan, M.; Hirata, J.; Tilly, H.; Flowers, C. R. |
| Abstract Title: | Five-year analysis of the POLARIX study: Prolonged follow-up confirms positive impact of polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) on outcomes |
| Meeting Title: | 66th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 144 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2024 Dec 7-10 |
| Meeting Location: | San Diego, CA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2024-11-05 |
| Start Page: | 469 |
| End Page: | 472 |
| Language: | English |
| ACCESSION: | WOS:001415654100019 |
| DOI: | 10.1182/blood-2024-197938 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract -- Source: Wos |
